A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

IZI Medical Products Announces the Launch of Vertefix® HV Cement with Insite™ Tracking Beads

IZI Medical Products, LLC (“IZI”), a leading manufacturer of interventional radiology devices and products to treat vertebral compression fractures, announces the official launch of Vertefix HV Cement (“Vertefix HV”).

Vertefix HV provides a unique solution that addresses the need for real-time flow visualization during cement injection for vertebroplasty and kyphoplasty procedures.

“Our goal in developing Vertefix HV was to give physicians a better way to track and control where cement is flowing during their procedures,” said Greg Groenke, CEO, IZI Medical Products. “The introduction of variable-sized barium particles with high viscosity makes this possible, improving outcomes and safety for patients.”

“Vertefix HV will help you control your cement and allow you to have excellent cement viscosity immediately after mixing. It has an optimal volume of cement with good working time and viscosity, along with great visualization so you can see when the cement is flowing and where it is going. The Insite beads are a great addition and now novel to all of the cements on the market. Bottom line is it’s the best cement I’ve used since I can remember,” said Dr. Douglas Beall, Chief of Services and Interventional Spine Services, Comprehensive Specialty Care, Edmond, Oklahoma.

“Improved visualization of cement has always been one of the goals to provide better safety with kyphoplasty and vertebroplasty. If you can visualize the cement better it makes the procedure safer, so the improved visualization by having variable-size barium particles is really nice,” said Dr. Jonathan Morris, Neuroradiologist.

The new Vertefix HV Cement with Insite tracking beads offers high viscosity and long working time and is an innovative enhancement to IZI’s vertebral augmentation portfolio. “We worked with physicians to find out what would really help them in vertebral augmentation procedures. Their input was insightful, and we’re pleased with what we’ve been able to deliver with Vertefix HV,” said Jovie Soriano, SVP Marketing and Business Development, IZI Medical Products.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy